Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
Published: 04 May 2026
Author: Towards Healthcare
Argo Biopharmaceutical Co, a clinical-stage small interfering RNA (siRNA) therapeutics company, announced that the first patient has been dosed in multiple Phase II studies of BW-40202, an investigational siRNA therapy targeting complement factor B (CFB).
It is designed to evaluate BW-40202 as a potential treatment for patients suffering from complement-mediated diseases, paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).
According to Towards Healthcare, the RNA Interference Therapy market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 5.71 billion in 2026 to approximately USD 24.96 billion by 2035, representing a compound annual growth rate (CAGR) of 17.8% from 2026 to 2035. Growth is driven by the increasing prevalence of genetic disorders and the growing burden of chronic diseases, which have driven the need for precise and targeted therapies like RNAi. Technological innovation has enhanced the safety and effectiveness of RNAi therapies, expanding their clinical applications.
About Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patients experience a range of symptoms, including severe anaemia, thrombosis, fatigue, hemoglobinuria, chronic kidney disease, and pulmonary hypertension. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hemolytic disorder characterised by complement-mediated red blood cell destruction (hemolysis), bone marrow failure, and severe thrombophilia.
Thromboembolism is the leading cause of mortality in patients with PNH, accounting for death with two known reasons, which are impacting morbidity and life expectancy of PNH patients. It offers precise targeting, longer-lasting efficacy, reduced dosing frequency, and improved safety and convenience, which is a promising new approach with the potential to deliver more effective, durable, safer, and more manageable treatment options.
About Argo Biopharma
It is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and speciality/rare diseases. Currently, Argo Biopharma has seven RNAi candidates in clinical development.
A recent report by Towards Healthcare highlights that the RNA Interference Therapy market is witnessing growth due to the focus on genetic research, which has led to a surge in the development of RNAi-based therapies, which are particularly effective in silencing disease-related genes. The rising burden of chronic diseases and the increasing incidence of rare genetic disorders have made RNAi therapies increasingly valuable for treatment.
North America dominates the RNA therapeutics market; this dominance is attributed to new RNAi product approvals and a surge in the incidence of new chronic diseases. The Asia Pacific region is growing at the fastest pace. This growth is driven by rising cancer prevalence and countries focusing on the development of liver-targeting RNAi therapies.